The Role of ITGAM in Systemic Lupus Erythematosus

Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Completed

Looking for future studies?

Key information

Conditions

Systemic Lupus Erythematosus Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Lupus Erythematosus, Systemic Skin and Connective Tissue Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Feinstein Institute for Medical Research

Manhasset, New York, 11030, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health
Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion criteria

History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease
History of cancer or lymphoma
Current use of aspirin, prednisone, or NSAID or any immunosuppressant
Self reported HIV

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus

Important dates

Study start: 2009
Primary completion: 2012
Study completion: 2012
First posted: Oct 28, 2010
Registry last updated: Jul 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed